Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CH505 HIV Vaccine Regimens in Healthy Adults
NCT07757802Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of DV901-NP, DV902-NP, CH505 TF mRNA-gp160, CH505 w24 mRNA-gp160 and ACU-026-001-1 in human immunodeficiency virus infection (HIV) (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Incidence of solicited local reactogenicity, Incidence of solicited systemic reactogenicity and 8 more. Planned start Dec 2026; status: recruiting.
02
Drugs
DV901-NPDV902-NPCH505 TF mRNA-gp160CH505 w24 mRNA-gp160ACU-026-001-1
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07757802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07757802.